Health News Releases

  • Today May 23
May 15, 2014 16:15
New analysis shows Boehringer Ingelheim’s Giotrif® (afatinib) is the first treatment to demonstrate significant overall survival benefit for patients with a specific type of lung cancer
For Ex-US and Ex-UK Media Only Boehringer Ingelheim today announced new overall survival results from a post-hoc analysis combining the data of two Phase III trials (LUX-Lung 3 and LUX-Lung 6). The
May 15, 2014 13:40
LFB SA Announces That First Patient Has Begun Treatment with New Coagulation Factor VIIa (Recombinant) in Global Phase 3 Clinical Trial in Hemophilia A and B with Inhibitors
LFB SA, through its U.S. subsidiary, announced today that the first patient has begun treatment with LR769 in a Phase 3 clinical trial of this novel recombinant form of human Factor VIIa in patients w
May 14, 2014 22:30
Wolters Kluwer Health, International AIDS Society Partner to Support Critical Clinical Decision Making
Wolters Kluwer Health (http://goo.gl/o2rWK), a leading global provider of information for healthcare professionals and students, announced today that it has partnered with the International AIDS Socie
May 14, 2014 20:05
Crescendo Bioscience's Vectra(R) DA Predicts Radiographic Progression in Patients With Early Rheumatoid Arthritis
Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (Nasdaq:MYGN), today announced the online publication of a new study in the journal Annals of the Rheumatic Diseases for Cresce
May 13, 2014 14:30
Dr. Paul A. Friedman Joins Verastem Board of Directors
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced the appointment of Paul A. Friedman, M.D. to its
May 13, 2014 11:25
Quintiles Announces Agreement to Acquire Encore Health Resources
As part of its continued efforts to strengthen and expand its service capabilities across the healthcare continuum, Quintiles today announced that it has signed an agreement to acquire Encore Health R
May 08, 2014 11:50
New study to investigate dabigatran etexilate for prevention of recurrent stroke in high-risk patients
For media outside of the U.S., the UK & Canada only Details of a new 6,000 patient study of dabigatran etexilate were announced today at the European Stroke Conference, Nice, France. The RE-SPECT E
May 07, 2014 21:45
New registry data highlight substantial global differences in stroke prevention for patients with an irregular heart beat
For media outside of the U.S., the UK & Canada only Boehringer Ingelheim today announces first worldwide data from the GLORIA™-AF Registry Programme highlighting substantial regional differences in
FightBack logo
May 07, 2014 18:05
Otsuka Wins European Marketing Authorization for Deltyba™ (delamanid)
Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced that the European Commission has granted a marketing authorization for Deltyba™ (delamanid) for use as part of an appropriate combination regim
May 07, 2014 17:20
Quintiles Executive to Present at Bank of America Merrill Lynch 2014 Health Care Conference
Quintiles CFO Kevin Gordon will present at the Bank of America Merrill Lynch 2014 Health Care Conference on Thursday, May 15, 2014 in Las Vegas at the Encore Wynn. The Quintiles presentation will b
May 07, 2014 13:55
AHRQ Publishes Third Edition of Quintiles-Led Registries User’s Guide
Quintiles today announced that the U.S. Agency for Healthcare Research and Quality (AHRQ) has published the third edition of “Registries for Evaluating Patient Outcomes: A User’s Guide.” Quintiles’ Re
May 02, 2014 14:45
ElectroCore: Two separate studies on the treatment of migraine headache with non invasive vagus nerve stimulation are being presented at the American Association of Neurology (AAN) meeting in Philadelphia
At the AAN meeting in Philadelphia, two separate studies showed that electroCore’s non invasive vagus nerve stimulation (nVNS) therapy was effective in helping patients with different types of migrain
May 01, 2014 19:00
Merrimack Pharmaceuticals Announces MM-398 Achieves Primary Endpoint of Overall Survival in Phase 3 Trial in Post-Gemcitabine Metastatic Pancreatic Cancer
Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that the combination of MM-398 with 5-fluorouracil (5-FU) and leucovorin achieved an overall survival of 6.1 months, a 1.9 month improveme
April 30, 2014 17:35
Boehringer Ingelheim to present highly anticipated Phase III data in IPF and COPD at ATS International Conference
For media outside UK, U.S. and Canada Boehringer Ingelheim announced today that the first results of the two confirmatory Phase III INPULSISTM trials, investigating nintedanib* in the treatment of
April 30, 2014 12:00
Asklepios Accelerates Investments in Equipment, Technology and Quality of Staff: Self-Imposed Claim as an Innovative Former in the Health System Makes Clear That the Safety of Patients and Employees is at the Focus
Asklepios Kliniken GmbH, holding company of the health care Group Asklepios, once again shows sustainable growth at all levels of the company. Asklepios invested in fiscal year 2013 mainly in modernis
VeinViewer Vision2, Christie's latest advancement in vein illumination.
April 28, 2014 21:00
Christie Medical Holdings Unveils Sixth Generation VeinViewer Vision2
Christie Medical Holdings (www.christiemed.com), Inc., the inventor and global leader of direct projection vascular imaging systems, today unveiled VeinViewer® Vision2 (http://goo.gl/ePxAmC). VeinView
April 28, 2014 15:55
Positive CHMP opinion for Pradaxa® in treatment of deep vein thrombosis and pulmonary embolism and prevention of repeat blood clots
For media outside of the U.S., the UK & Canada only Boehringer Ingelheim announces that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a
April 25, 2014 14:00
Quintiles and Biogen Idec Announce Comprehensive Clinical Development Partnership
Quintiles, the world’s largest provider of biopharmaceutical development and commercial outsourcing services, and Biogen Idec (NASDAQ: BIIB) have entered into a five-year strategic clinical developmen
April 18, 2014 14:00
Quintiles Recognized as Industry Leader in Phase II/III Research for Second Year in a Row
For the second year in a row, Quintiles has been named the industry leader that best differentiates itself on service quality for Phase II/III research in Industry Standard Research’s (ISR) 2014 (http
April 17, 2014 19:50
Volasertib, Boehringer Ingelheim´s investigational treatment of acute myeloid leukaemia, is granted ‘orphan drug designation’ in the EU and the US
For media outside of the US and UK only Boehringer Ingelheim announced today that the US Food and Drug Administration (FDA) and the European Commission have granted volasertib* ‘orphan drug designa
April 17, 2014 15:45
ASCO, ESMO, EORTC, ESO, and UICC Continue Endorsing the WIN Symposium Series in 2014
Five major cancer organizations which have endorsed previous events in the WIN Symposium Series, are also endorsing the WIN 2014 Symposium, to be held in Paris, June 23 - 24. The high scientific level
April 15, 2014 19:20
Irvine Scientific Announces Expansion of BalanCD™ Product Line to Serve Vaccine Market
Irvine Scientific (www.irvinesci.com) is pleased to announce the launch of its BalanCD™ MDCK (http://goo.gl/WBpyez) cell culture medium, a next generation cell culture product responding to today’s re
April 15, 2014 11:25
Real-World Patient Survey Data Shows Negative Impact of Nocturia
New patient survey data presented today at the European Association of Urology (EAU 14) congress, showed that nocturia (waking to void one or more times a night followed by sleep), has a strong negati
April 14, 2014 13:35
New Studies Show Health Risks from Wireless Tech: Warnings from the BioInitiative Working Group
The BioInitiative Working Group says evidence for health risk from wireless tech is growing stronger and warrants immediate action. The Group released a mid-year update covering new science studies fr
April 10, 2014 12:00
Quintiles’ First Quarter 2014 Earnings Call Scheduled for Thursday, May 1st
Quintiles Transnational Holdings Inc. (NYSE: Q) will release its financial results for the first quarter of 2014 prior to its quarterly earnings call on Thursday, May 1, 2014, at 8:00 a.m. EDT. The
25 per page50 per page75 per page100 per page